LeadingTac Overview

  • Year Founded
  • 2019

Year Founded

  • Status
  • Private

  • Employees
  • 30

Employees

  • Latest Deal Type
  • Series B

  • Latest Deal Amount
  • $31.1M

  • Investors
  • 8

LeadingTac General Information

Description

Developer of small-molecule innovative therapeutics intended for the treatment of autoimmune and tumor diseases. The company offers research platforms and drug candidates leveraging targeted protein degradation technologies, proprietary intracellular and extracellular protein ubiquitination systems, modular small molecule compounds with E3 ligase recruitment, secure clinical trial progression infrastructure, and global intellectual property coverage, enabling biopharma developers, clinicians, and research collaborators to advance first in class therapeutic candidates through preclinical and clinical stages with enhanced target specificity and streamlined development pathways.

Contact Information

Website
www.leadingtac.com
Formerly Known As
Shanghai Lingtai Biopharmaceutical Technology Co., Ltd.
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Room 209
  • Number 781 Cailun Road, China Pilot Free Trade Zone
  • Shanghai, Shanghai 201203
  • China
+86 021
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Life Sciences, Oncology
Corporate Office
  • Room 209
  • Number 781 Cailun Road, China Pilot Free Trade Zone
  • Shanghai, Shanghai 201203
  • China
+86 021

LeadingTac Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

LeadingTac Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Early Stage VC (Series B) 18-Dec-2025 $31.1M Completed Clinical Trials - Phase 1
3. Early Stage VC (Series A) 24-Jun-2024 Completed Clinical Trials - Phase 1
2. Early Stage VC 18-Nov-2021 $10.9M $13.8M Completed Generating Revenue
1. Seed Round 12-Nov-2019 $2.84M $2.84M Completed Startup
To view LeadingTac’s complete valuation and funding history, request access »

LeadingTac Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

LeadingTac Investors (8)

Investor Name Investor Type Holding Investor Since Participating Rounds
CDH Investments PE/Buyout Minority
Hankang Capital Growth/Expansion Minority
Kangcheng Capital Growth/Expansion Minority
Lapam Capital Venture Capital Minority
Tianrui Fengnian Venture Capital Minority
You’re viewing 5 of 8 investors. Get the full list »

Ready to get started?

Request a free trial

LeadingTac FAQs

  • When was LeadingTac founded?

    LeadingTac was founded in 2019.

  • Where is LeadingTac headquartered?

    LeadingTac is headquartered in Shanghai, China.

  • What is the size of LeadingTac?

    LeadingTac has 30 total employees.

  • What industry is LeadingTac in?

    LeadingTac’s primary industry is Drug Discovery.

  • Is LeadingTac a private or public company?

    LeadingTac is a Private company.

  • What is LeadingTac’s current revenue?

    The current revenue for LeadingTac is .

  • How much funding has LeadingTac raised over time?

    LeadingTac has raised $63.7M.

  • Who are LeadingTac’s investors?

    CDH Investments, Hankang Capital, Kangcheng Capital, Lapam Capital, and Tianrui Fengnian are 5 of 8 investors who have invested in LeadingTac.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process